MindWalk Holdings Corp.
$1.27
0%
2026-04-21 07:24:02
www.mindwalkai.com
NCM: HYFT
Explore MindWalk Holdings Corp. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$59.32 M
Current Price
$1.27
52W High / Low
$3.25 / $0.4
Stock P/E
—
Book Value
$0.23
Dividend Yield
—
ROCE
-34.42%
ROE
-58.82%
Face Value
—
EPS
$-0.1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
81
Beta
0.64
Debt / Equity
23.71
Current Ratio
3.74
Quick Ratio
1.85
Forward P/E
—
Price / Sales
1.78
Enterprise Value
$42.6 M
EV / EBITDA
-4.06
EV / Revenue
1.52
Rating
None
Target Price
$4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 2. | Vaxcyte, Inc. | $61.4 | — | $8.86 B | — | -33.02% | -25.59% | $65 / $28.09 | $20.49 |
| 3. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
| 4. | Nutriband Inc. | $4.2 | — | $51.13 M | — | -103.12% | -1.36% | $11.68 / $3.42 | $0.62 |
| 5. | Plus Therapeutics, Inc. | $7.3 | — | $50.09 M | — | -381.4% | 903.94% | $30.5 / $2.9 | $0.72 |
| 6. | Cadrenal Therapeutics, Inc. | $5.25 | — | $13.09 M | — | -491.51% | -2.6% | $17.5 / $4.21 | $1.17 |
| 7. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|---|
| Sales | 4.16 M | 4.12 M | 3.16 M | 6.98 M | 2.73 M | — |
| Operating Profit | -3.66 M | -2.76 M | -4.15 M | -1.46 M | -3.67 M | — |
| Net Profit | -3.93 M | -3.19 M | -2.96 M | -2.16 M | -21.52 M | — |
| EPS in Rs | -0.08 | -0.07 | -0.06 | -0.05 | -0.46 | -0.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 24.52 M | 24.52 M | 20.66 M | 19.36 M |
| Operating Profit | -12.2 M | -13.76 M | -25.61 M | -16.67 M |
| Net Profit | -30.23 M | -26.11 M | -26.56 M | -16.71 M |
| EPS in Rs | -0.65 | -0.56 | -0.57 | -0.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 44.44 M | 59.99 M | 77.81 M | 93.65 M |
| Total Liabilities | 20.82 M | 24.31 M | 20.01 M | 18.36 M |
| Equity | 23.63 M | 35.68 M | 57.8 M | 75.28 M |
| Current Assets | 18.75 M | 11.49 M | 16.79 M | 37.47 M |
| Current Liabilities | 9.01 M | 8.12 M | 5.92 M | 9.29 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.41 M | -3.18 M | -19.83 M | -9.92 M |
| Investing CF | -0.8 M | -1.56 M | -1.97 M | -5.21 M |
| Financing CF | 14.89 M | 1.02 M | -0.62 M | 2.88 M |
| Free CF | -7.21 M | -4.58 M | -21.33 M | -11.18 M |
| Capex | -0.8 M | -1.4 M | -1.5 M | -1.26 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 18.65% | 6.72% | — | — |
| Earnings Growth % | 1.68% | -58.96% | — | — |
| Profit Margin % | -106.51% | -128.53% | -86.29% | — |
| Operating Margin % | -56.13% | -123.93% | -86.1% | — |
| Gross Margin % | 49.16% | 55.95% | 56.72% | — |
| EBITDA Margin % | -93.6% | -101.8% | -61.94% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.